Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing
Market Whales and Their Recent Bets on REGN Options
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): 'Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling'
US MOVERS&SHAKERS Sep 23-Sep 27, 2024
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
S&P 500 Extends Winning Streak to Third Week as Materials Sector Climbs
News Highlights: Top Company News of the Day - Friday at 1 PM ET
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Express News | Regeneron Pharmaceuticals Shares up 1.9% After US FDA Approves Co and Partner Sanofi's Drug to Treat 'smoker's Lung'
Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD
Express News | Dupixent® (Dupilumab) Approved in China as the First-Ever Biologic Medicine for Patients With Chronic Obstructive Pulmonary Disease (Copd)
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024